Teva and Intel create a wearable against the disease

[ad_1]

Teva Pharamaceutical Industries and Intel have decided to partner to create a smart health connected device that can monitoring Huntington's disease patients. This is a major project at the crossroads of medical science and technology.

The Israeli pharmaceutical company Teva Pharmaceutical Industries has announced its collaboration with Intel. Together, the two firms will develop a smart health smart health connected object capable of monitoring patients with Huntington's disease, a fatal degenerative disease.

This inherited disease causes progressive degeneration of nerve cells in the brain. This degeneration gradually leads to the decline of motor controls and mental stability. There is currently no medicine to stop this phenomenon. As a rule, patients die between 15 and 25 years after the onset of the disease. However, some medications help fight the symptoms.

A smart health smart health connected object smart health connected to the Intel cloud to fight against Huntington

The device will be deployed as part of an already advanced study on Huntington. Patients will wear a smart health connected watch with sensors that constantly measure vital characteristics, coupled with a smartphone. The collected data will be transferred directly to a cloud platform developed by Intel. This platform will interpret this data, almost in real time, to detect symptoms of motor disorders.

With the collaboration of companies like Teva and Intel, the border between medicine and technology is disappearing in favor of the fight against chronic diseases through high-tech devices combining biology, software and advanced hardware. The objective is to to prove that drugs can preserve large groups of healthy patients, and thus encourage the goodwill of insurers. Drug manufacturers will be able to offer services that go beyond the mere prescription of drugs.

Medicine and technology are increasingly linked

For their part, companies like Apple, Samsung or Alphabet are trying to find new health apps to launch a new wave of smart health connected objects. Earlier this month, the French pharmaceutical company Sanofi partnered with Verily, the scientific unit of Alphabet, to combine technological devices with medical services to fight against diabetes.

In August, GlaxoSmithKline and Verily created a new company focused on fighting diseases by targeting the body's electrical signals. This is a new medical field called bioelectronics.

Similarly, Verily is working on the development of a smart health connected contact lens in partnership with Switzerland's Novartis. This smart lens ships a glucose sensor to help monitoring diabetes. In addition, Biogenis works with Alphabet to study the progression of multiple sclerosis.

[ad_2]